Monte Rosa Therapeutics Stock Technical Analysis
| GLUE Stock | USD 20.93 0.05 0.24% |
As of the 4th of February, Monte Rosa secures the Risk Adjusted Performance of 0.1101, downside deviation of 4.25, and Mean Deviation of 4.29. Monte Rosa Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Monte Rosa Therapeutics jensen alpha, as well as the relationship between the potential upside and skewness to decide if Monte Rosa Therapeutics is priced some-what accurately, providing market reflects its recent price of 20.93 per share. Given that Monte Rosa Therapeutics has jensen alpha of 1.02, we recommend you to check Monte Rosa's last-minute market performance to make sure the company can sustain itself at a future point.
Monte Rosa Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Monte, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to MonteMonte Rosa's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Monte Rosa Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 33.8 | Strong Buy | 9 | Odds |
Most Monte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Monte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Monte Rosa Therapeutics, talking to its executives and customers, or listening to Monte conference calls.
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Monte Rosa 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Monte Rosa's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Monte Rosa.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Monte Rosa on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Monte Rosa Therapeutics or generate 0.0% return on investment in Monte Rosa over 90 days. Monte Rosa is related to or competes with Day One, Arvinas, Replimune, Theravance Biopharma, ArriVent BioPharma, Geron, and Vir Biotechnology. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision... More
Monte Rosa Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Monte Rosa's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Monte Rosa Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.25 | |||
| Information Ratio | 0.1305 | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | (6.07) | |||
| Potential Upside | 11.18 |
Monte Rosa Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monte Rosa's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Monte Rosa's standard deviation. In reality, there are many statistical measures that can use Monte Rosa historical prices to predict the future Monte Rosa's volatility.| Risk Adjusted Performance | 0.1101 | |||
| Jensen Alpha | 1.02 | |||
| Total Risk Alpha | 0.5736 | |||
| Sortino Ratio | 0.2263 | |||
| Treynor Ratio | (4.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Monte Rosa's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Monte Rosa February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1101 | |||
| Market Risk Adjusted Performance | (4.26) | |||
| Mean Deviation | 4.29 | |||
| Semi Deviation | 3.7 | |||
| Downside Deviation | 4.25 | |||
| Coefficient Of Variation | 726.27 | |||
| Standard Deviation | 7.38 | |||
| Variance | 54.42 | |||
| Information Ratio | 0.1305 | |||
| Jensen Alpha | 1.02 | |||
| Total Risk Alpha | 0.5736 | |||
| Sortino Ratio | 0.2263 | |||
| Treynor Ratio | (4.27) | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | (6.07) | |||
| Potential Upside | 11.18 | |||
| Downside Variance | 18.1 | |||
| Semi Variance | 13.68 | |||
| Expected Short fall | (5.07) | |||
| Skewness | 3.55 | |||
| Kurtosis | 19.72 |
Monte Rosa Therapeutics Backtested Returns
Monte Rosa is slightly risky given 3 months investment horizon. Monte Rosa Therapeutics has Sharpe Ratio of 0.14, which conveys that the firm had a 0.14 % return per unit of risk over the last 3 months. We are able to break down and analyze data for thirty different technical indicators, which can help you to evaluate if expected returns of 1.04% are justified by taking the suggested risk. Use Monte Rosa Therapeutics Downside Deviation of 4.25, mean deviation of 4.29, and Risk Adjusted Performance of 0.1101 to evaluate company specific risk that cannot be diversified away. Monte Rosa holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Monte Rosa are expected to decrease at a much lower rate. During the bear market, Monte Rosa is likely to outperform the market. Use Monte Rosa Therapeutics sortino ratio, skewness, price action indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Monte Rosa Therapeutics.
Auto-correlation | 0.64 |
Good predictability
Monte Rosa Therapeutics has good predictability. Overlapping area represents the amount of predictability between Monte Rosa time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Monte Rosa Therapeutics price movement. The serial correlation of 0.64 indicates that roughly 64.0% of current Monte Rosa price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.64 | |
| Spearman Rank Test | 0.38 | |
| Residual Average | 0.0 | |
| Price Variance | 11.89 |
Monte Rosa technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Monte Rosa Therapeutics Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Monte Rosa Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Monte Rosa Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Monte Rosa Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Monte Rosa Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Monte Rosa Therapeutics price pattern first instead of the macroeconomic environment surrounding Monte Rosa Therapeutics. By analyzing Monte Rosa's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Monte Rosa's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Monte Rosa specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2025 | 2026 (projected) | Interest Debt Per Share | 0.52 | 0.66 | Revenue Per Share | 0.92 | 0.82 |
Monte Rosa February 4, 2026 Technical Indicators
Most technical analysis of Monte help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Monte from various momentum indicators to cycle indicators. When you analyze Monte charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1101 | |||
| Market Risk Adjusted Performance | (4.26) | |||
| Mean Deviation | 4.29 | |||
| Semi Deviation | 3.7 | |||
| Downside Deviation | 4.25 | |||
| Coefficient Of Variation | 726.27 | |||
| Standard Deviation | 7.38 | |||
| Variance | 54.42 | |||
| Information Ratio | 0.1305 | |||
| Jensen Alpha | 1.02 | |||
| Total Risk Alpha | 0.5736 | |||
| Sortino Ratio | 0.2263 | |||
| Treynor Ratio | (4.27) | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | (6.07) | |||
| Potential Upside | 11.18 | |||
| Downside Variance | 18.1 | |||
| Semi Variance | 13.68 | |||
| Expected Short fall | (5.07) | |||
| Skewness | 3.55 | |||
| Kurtosis | 19.72 |
Monte Rosa February 4, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Monte stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.00 | ||
| Daily Balance Of Power | 1.00 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 20.91 | ||
| Day Typical Price | 20.91 | ||
| Price Action Indicator | 0.05 | ||
| Market Facilitation Index | 0.05 |
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities |